Lotus Partners

Industry

Developing Practice Tier 2 Thin-Margin Turnaround

CPG, Food & AgTech

An enterprise ingredient sale is won in the R&D director’s evidence review, not the shopper’s imagination. Lab data, patent grounding, and regulatory-claim logic, sequenced before the commercial ask, decide whether a sample request ever happens.

The path to volume for a food or ag-tech innovator runs through a manufacturer’s formulation team, and that buyer purchases certainty: verifiable science, claims that survive legal review, supply that survives an audit. Consumer branding is the expensive detour; the evidence file is the road.

Industry research

The economics

5.6g per RACC, the fiber-claim line 20% of the Daily Value per reference amount customarily consumed — the line between marketing copy and a legal “excellent source of fiber” claim. The firm has this logic in working code: a client’s ROI calculator that checks a manufacturer’s blend against the threshold live.
Distribution the constraint that decides the category The category’s recurring tragedy — observable across functional food and beverage — is the genuinely superior product that never converts to scaled retail revenue. Channel machinery fails before the science does.
Expiring every patent moat, by design A patent is a moat with a countdown. The durable version is rebuilt while it runs — certification seals, clinical data, locked supply contracts — a proof stack that outlives the filing.

FIGURES FROM THE FIRM’S RESEARCH · SOURCES ON REQUEST

Growth opportunities

Where the 2× lives

  1. The evidence file, sequenced

    Scientific authority arranged ahead of the commercial ask: verified lab data, the patent story, the citations, then the ROI case, then the sample request. Enterprise food buyers move through technical validation before procurement ever sees a price — the buyer journey runs in that order.

  2. Regulatory claims as working logic

    Labeling law encoded where the buyer can test it: thresholds computed live in the selling tools, claim language pre-drafted against the standard it invokes, so counsel reviews a position rather than builds one. Claims literacy is a credibility asset a formulation team can feel — and it shortens the legal review it never replaces.

  3. The ingredient position

    Selling the ingredient into other companies’ brands instead of fighting for shelf as one: licensing economics recur, ride the customer’s distribution, and change what the business is worth — the model shift that moves thin commodity margins.

  4. The moat rebuild

    Patent-expiry planning started years early: the certification seal, the clinical file, and the long-dated supply contracts assembled while exclusivity still holds, so the pricing power survives the cliff.

Our perspective

What most firms get wrong

Marketing to the shopper when the buyer is a scientist

The reflex in food innovation is consumer-brand spend — packaging, social, retail placement. But the volume path is B2B, and an R&D director reads a beautiful brand without a checkable evidence file as a warning, not an invitation. Credibility sequenced before commerce is the entire game.

Where we’d start

An evidence audit against one named target manufacturer: every claim classified as verified, pending, or unsupported; the label claims the product can honestly clear computed against the actual regulatory thresholds; and the technical-validation-to-sample-request path sequenced.

Put it to us

How we engage here